Novo Nordisk CEO Mike Doustdar sits down with Jim Cramer

Jim Cramer interviews Novo Nordisk CEO Mike Doustdar after a beat-and-raise quarter. They discuss the launch of Novo's oral GLP-1 pill, which Doustdar calls the best product launch in pharmaceutical history, and why guidance remains negative due to deliberate injectable price cuts. Cramer argues the stock looks too cheap because the pill may improve the company's trajectory. - Novo Nordisk reported a beat-and-raise quarter but the stock initially fell nearly 6%. - Novo's oral GLP-1 pill has reached 1.5 million global patients and over 5 million US prescriptions. - Doustdar calls the pill launch the best product launch in pharmaceutical history. - Management improved guidance midpoint but kept it negative because of deliberate price cuts on injectable Ozempic/Wegovy. - Eli Lilly is gaining market share and is more diversified than Novo Nordisk. - Doustdar highlights Novo's pill efficacy of 17% weight loss versus Lilly's 12%. - Cramer sees a good runway and views Novo Nordisk stock as too cheap.